Ascendis launches growth hormone Skytrofa in the US

In August, the company brought home an FDA approval for the once-weekly growth hormone Skytrofa. The biotech company Ascendis Pharma is now ready to send the drug to market.

BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Published: 15.10.21 at 14:50

A month and a half since securing the approval from the US Food and Drug Administration (FDA), Ascendis Pharma is ready to market the drug Skytrofa, which addresses the need of children suffering from growth hormone deficiency, informs the company in a press release.

Parallel to the launch, Ascendis is initiating a patient support program to help increase the access to the hormone, which is a prescription drug sold at specialty pharmacies in the US, before it is included in official US health programs.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Photo: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.